Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!
From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

Tom French: 28 July 2025

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future This article traces the evolution of API-in-capsule (AIC)...

Read More
What does Annex 1 mean for the cell & gene industry? Insights from 3P innovation.

What does Annex 1 mean for the cell & gene industry? Insights from 3P innovation.

Charles Pilato: 17 July 2025

The revision of EU GMP Annex 1 has redefined expectations for sterile manufacturing across the life sciences sector and nowhere is this felt more...

Read More
How do we reduce your Environmental Cost of Ownership (ECO)?

How do we reduce your Environmental Cost of Ownership (ECO)?

David Johnson: 16 July 2025

Today’s pharmaceutical landscape positions 'sustainability' as an operational imperative. Manufacturers face increasing regulatory, societal, and...

Read More